13F Data
13F filer · CIK 1910264

SR One Capital Management, LP

Redwood City, CA · filing since Q4 2021 · last filing Aug 12, 2026
Reported value
$1.0B
+$123.6M vs prior
Positions
15
New / sold out
3 / 2
Added / reduced
1 / 0
Turnover
21.2%
buys $207.6M · sells $290.5M
Top-10 weight
95.1%

Biggest buys vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
NewAvalyn Pharma, Inc+3,308,649–+$108.9M
NewOdyssey Therapeutics, Inc.+3,794,883–+$71.0M
NewMobia Medical, Inc+1,986,072–+$26.6M
AddedORIC Pharmaceuticals, Inc.+100,455+2.2%+$1.1M

Biggest sells vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
Sold outArcellx, Inc.-2,346,630-100.0%$-269.4M
Sold outOruka Therapeutics, Inc-430,330-100.0%$-21.1M

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q4 2021: $176.9MQ1 2022: $195.3MQ2 2022: $204.3MQ3 2022: $218.7MQ4 2022: $273.9MQ1 2023: $268.5MQ2 2023: $231.9MQ3 2023: $195.1MQ4 2023: $238.2MQ1 2024: $364.1MQ2 2024: $319.4MQ3 2024: $498.7MQ4 2024: $410.1MQ1 2025: $389.3MQ2 2025: $461.4MQ3 2025: $691.4MQ4 2025: $706.4MQ1 2026: $915.4MQ2 2026: $1.0B
Q4 2021Q2 2026

Holdings · Q2 2026

#SecuritySharesValueWeight
1Veradermics, Inc.COMMON STOCK2,401,868$295.3M28.42%
2Zenas BioPharma, IncCOMMON STOCK5,037,854$127.9M12.31%
3CRISPR Therapeutics AGCOMMON SHARES2,038,763$111.2M10.70%
4Avalyn Pharma, IncCOMMON STOCK3,308,649$108.9M10.48%
5Design Therapeutics, Inc.COMMON STOCK6,526,476$94.4M9.09%
6Odyssey Therapeutics, Inc.COMMON STOCK3,794,883$71.0M6.83%
7Alumis Inc.COMMON STOCK1,959,896$55.2M5.31%
8ORIC Pharmaceuticals, Inc.COMMON STOCK4,615,384$50.0M4.81%
9Mineralys Therapeutics Inc.COMMON STOCK1,563,966$42.2M4.06%
10ARS Pharmaceuticals, Inc.COMMON STOCK4,012,903$32.1M3.09%
5 more rows. Subscribe for $29/month to see every row, download the data and use the API.